{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:24:24Z","timestamp":1791415464699,"version":"4.3.3"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-025-02755-1","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T15:20:15Z","timestamp":1745853615000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["EIDD-2801 resists to infection and co-infection of SARS-CoV-2 and influenza virus"],"prefix":"10.1186","volume":"22","author":[{"given":"Bingshuo","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongbo","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beilei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junkui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuwen","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobin","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"2755_CR1","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","volume":"382","author":"Q Li","year":"2020","unstructured":"Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel Coronavirus\u2013Infected pneumonia. N Engl J Med. 2020;382:1199\u2013207. https:\/\/doi.org\/10.1056\/NEJMoa2001316.","journal-title":"N Engl J Med"},{"key":"2755_CR2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497\u2013506. https:\/\/doi.org\/10.1016\/S0140-6736(20)30183-5.","journal-title":"Lancet"},{"key":"2755_CR3","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.it.2020.10.004","volume":"41","author":"AG Harrison","year":"2020","unstructured":"Harrison AG, Lin T, Wang P. Mechanisms of SARS-CoV-2 transmission and pathogenesis. Trends Immunol. 2020;41:1100\u201315. https:\/\/doi.org\/10.1016\/j.it.2020.10.004.","journal-title":"Trends Immunol"},{"key":"2755_CR4","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41586-020-2342-5","volume":"583","author":"SF Sia","year":"2020","unstructured":"Sia SF, Yan L-M, Chin AWH, Fung K, Choy K-T, Wong AYL, et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature. 2020;583:834\u20138. https:\/\/doi.org\/10.1038\/s41586-020-2342-5.","journal-title":"Nature"},{"key":"2755_CR5","doi-asserted-by":"publisher","unstructured":"Chan JF-W, Zhang AJ, Yuan S, Poon VK-M, Chan CC-S, Lee AC-Y, et al. Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in a golden Syrian Hamster model: implications for disease pathogenesis and transmissibility. Clin Infect Dis. 2020;ciaa325. https:\/\/doi.org\/10.1093\/cid\/ciaa325.","DOI":"10.1093\/cid\/ciaa325"},{"key":"2755_CR6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41586-021-03944-y","volume":"599","author":"P Mlcochova","year":"2021","unstructured":"Mlcochova P, Kemp SA, Dhar MS, Papa G, Meng B, Ferreira IATM, et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature. 2021;599:114\u20139. https:\/\/doi.org\/10.1038\/s41586-021-03944-y.","journal-title":"Nature"},{"key":"2755_CR7","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/j.cell.2021.03.013","volume":"184","author":"WF Garcia-Beltran","year":"2021","unstructured":"Garcia-Beltran WF, Lam EC, St. Denis K, Nitido AD, Garcia ZH, Hauser BM, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184:2372\u2013e23839. https:\/\/doi.org\/10.1016\/j.cell.2021.03.013.","journal-title":"Cell"},{"key":"2755_CR8","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1016\/j.cell.2021.02.037","volume":"184","author":"D Zhou","year":"2021","unstructured":"Zhou D, Dejnirattisai W, Supasa P, Liu C, Mentzer AJ, Ginn HM, et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced Sera. Cell. 2021;184:2348\u2013e23616. https:\/\/doi.org\/10.1016\/j.cell.2021.02.037.","journal-title":"Cell"},{"key":"2755_CR9","doi-asserted-by":"publisher","first-page":"e1128","DOI":"10.1093\/cid\/ciab721","volume":"75","author":"SWX Ong","year":"2022","unstructured":"Ong SWX, Chiew CJ, Ang LW, Mak TM, Cui L, Toh MPHS, et al. Clinical and virological features of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern: A retrospective cohort study comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta). Clin Infect Dis. 2022;75:e1128\u201336. https:\/\/doi.org\/10.1093\/cid\/ciab721.","journal-title":"Clin Infect Dis"},{"key":"2755_CR10","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","volume":"386","author":"N Andrews","year":"2022","unstructured":"Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med. 2022;386:1532\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2119451.","journal-title":"N Engl J Med"},{"key":"2755_CR11","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","volume":"596","author":"D Planas","year":"2021","unstructured":"Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596:276\u201380. https:\/\/doi.org\/10.1038\/s41586-021-03777-9.","journal-title":"Nature"},{"key":"2755_CR12","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.cell.2023.12.026","volume":"187","author":"P Qu","year":"2024","unstructured":"Qu P, Xu K, Faraone JN, Goodarzi N, Zheng Y-M, Carlin C, et al. Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and flip variants. Cell. 2024;187:585\u2013e5956. https:\/\/doi.org\/10.1016\/j.cell.2023.12.026.","journal-title":"Cell"},{"key":"2755_CR13","doi-asserted-by":"publisher","first-page":"e61312","DOI":"10.7554\/eLife.61312","volume":"9","author":"Y Weisblum","year":"2020","unstructured":"Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JC, et al. Escape from neutralizing antibodies by SARS-CoV-2 Spike protein variants. eLife. 2020;9:e61312. https:\/\/doi.org\/10.7554\/eLife.61312.","journal-title":"eLife"},{"key":"2755_CR14","doi-asserted-by":"publisher","unstructured":"Kim D, Quinn J, Pinsky B, Shah NH, Brown I. Rates of Co-infection between SARS-CoV-2 and other respiratory pathogens. JAMA 2020;323:2085. https:\/\/doi.org\/10.1001\/jama.2020.6266","DOI":"10.1001\/jama.2020.6266"},{"key":"2755_CR15","doi-asserted-by":"publisher","first-page":"3934","DOI":"10.1038\/s41598-021-83642-x","volume":"11","author":"KW Kim","year":"2021","unstructured":"Kim KW, Deveson IW, Pang CNI, Yeang M, Naing Z, Adikari T, et al. Respiratory viral co-infections among SARS-CoV-2 cases confirmed by Virome capture sequencing. Sci Rep. 2021;11:3934. https:\/\/doi.org\/10.1038\/s41598-021-83642-x.","journal-title":"Sci Rep"},{"key":"2755_CR16","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jmii.2020.05.013","volume":"53","author":"C-C Lai","year":"2020","unstructured":"Lai C-C, Wang C-Y, Hsueh P-R. Co-infections among patients with COVID-19: the need for combination therapy with non-anti-SARS-CoV-2 agents? J Microbiol Immunol Infect. 2020;53:505\u201312. https:\/\/doi.org\/10.1016\/j.jmii.2020.05.013.","journal-title":"J Microbiol Immunol Infect"},{"key":"2755_CR17","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jinf.2020.05.046","volume":"81","author":"L Lansbury","year":"2020","unstructured":"Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020;81:266\u201375. https:\/\/doi.org\/10.1016\/j.jinf.2020.05.046.","journal-title":"J Infect"},{"key":"2755_CR18","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1093\/infdis\/jiy184","volume":"218","author":"KF Chan","year":"2018","unstructured":"Chan KF, Carolan LA, Korenkov D, Druce J, McCaw J, Reading PC, et al. Investigating viral interference between influenza A virus and human respiratory syncytial virus in a ferret model of infection. J Infect Dis. 2018;218:406\u201317. https:\/\/doi.org\/10.1093\/infdis\/jiy184.","journal-title":"J Infect Dis"},{"key":"2755_CR19","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/irv.12020","volume":"7","author":"E Goka","year":"2013","unstructured":"Goka E, Vallely P, Mutton K, Klapper P. Influenza A viruses dual and multiple infections with other respiratory viruses and risk of hospitalisation and mortality. Influenza Resp Viruses. 2013;7:1079\u201387. https:\/\/doi.org\/10.1111\/irv.12020.","journal-title":"Influenza Resp Viruses"},{"key":"2755_CR20","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1002\/jmv.25499","volume":"91","author":"P Zhong","year":"2019","unstructured":"Zhong P, Zhang H, Chen X, Lv F. Clinical characteristics of the lower respiratory tract infection caused by a single infection or coinfection of the human parainfluenza virus in children. J Med Virol. 2019;91:1625\u201332. https:\/\/doi.org\/10.1002\/jmv.25499.","journal-title":"J Med Virol"},{"key":"2755_CR21","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1016\/j.chest.2020.07.061","volume":"158","author":"K Murphy","year":"2020","unstructured":"Murphy K. SARS CoV-2 detection from upper and lower respiratory tract specimens. Chest. 2020;158:1804\u20135. https:\/\/doi.org\/10.1016\/j.chest.2020.07.061.","journal-title":"Chest"},{"key":"2755_CR22","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.2353\/ajpath.2007.070248","volume":"171","author":"D Van Riel","year":"2007","unstructured":"Van Riel D, Munster VJ, De Wit E, Rimmelzwaan GF, Fouchier RAM, Osterhaus ADME, et al. Human and avian influenza viruses target different cells in the lower respiratory tract of humans and other mammals. Am J Pathol. 2007;171:1215\u201323. https:\/\/doi.org\/10.2353\/ajpath.2007.070248.","journal-title":"Am J Pathol"},{"key":"2755_CR23","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1126\/science.abb2762","volume":"367","author":"R Yan","year":"2020","unstructured":"Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367:1444\u20138. https:\/\/doi.org\/10.1126\/science.abb2762.","journal-title":"Science"},{"key":"2755_CR24","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41422-021-00473-1","volume":"31","author":"L Bai","year":"2021","unstructured":"Bai L, Zhao Y, Dong J, Liang S, Guo M, Liu X, et al. Coinfection with influenza A virus enhances SARS-CoV-2 infectivity. Cell Res. 2021;31:395\u2013403. https:\/\/doi.org\/10.1038\/s41422-021-00473-1.","journal-title":"Cell Res"},{"key":"2755_CR25","doi-asserted-by":"publisher","first-page":"e01791","DOI":"10.1128\/jvi.01791-21","volume":"96","author":"Y Huang","year":"2022","unstructured":"Huang Y, Skarlupka AL, Jang H, Blas-Machado U, Holladay N, Hogan RJ, et al. SARS-CoV-2 and influenza A virus coinfections in ferrets. J Virol. 2022;96:e01791\u201321. https:\/\/doi.org\/10.1128\/jvi.01791-21.","journal-title":"J Virol"},{"key":"2755_CR26","doi-asserted-by":"publisher","first-page":"e128","DOI":"10.1016\/j.jinf.2020.05.041","volume":"81","author":"X Zheng","year":"2020","unstructured":"Zheng X, Wang H, Su Z, Li W, Yang D, Deng F, et al. Co-infection of SARS-CoV-2 and influenza virus in early stage of the COVID-19 epidemic in Wuhan, China. J Infect. 2020;81:e128\u20139. https:\/\/doi.org\/10.1016\/j.jinf.2020.05.041.","journal-title":"J Infect"},{"key":"2755_CR27","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.3201\/eid2606.200299","volume":"26","author":"X Wu","year":"2020","unstructured":"Wu X, Cai Y, Huang X, Yu X, Zhao L, Wang F, et al. Co-infection with SARS-CoV-2 and influenza A virus in patient with pneumonia, China. Emerg Infect Dis. 2020;26:1324\u20136. https:\/\/doi.org\/10.3201\/eid2606.200299.","journal-title":"Emerg Infect Dis"},{"key":"2755_CR28","doi-asserted-by":"publisher","first-page":"e0009997","DOI":"10.1371\/journal.pntd.0009997","volume":"15","author":"J Zheng","year":"2021","unstructured":"Zheng J, Chen F, Wu K, Wang J, Li F, Huang S, et al. Clinical and virological impact of single and dual infections with influenza A (H1N1) and SARS-CoV-2 in adult inpatients. PLoS Negl Trop Dis. 2021;15:e0009997. https:\/\/doi.org\/10.1371\/journal.pntd.0009997.","journal-title":"PLoS Negl Trop Dis"},{"key":"2755_CR29","doi-asserted-by":"publisher","first-page":"eaax5866","DOI":"10.1126\/scitranslmed.aax5866","volume":"11","author":"M Toots","year":"2019","unstructured":"Toots M, Yoon J-J, Cox RM, Hart M, Sticher ZM, Makhsous N, et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med. 2019;11:eaax5866. https:\/\/doi.org\/10.1126\/scitranslmed.aax5866.","journal-title":"Sci Transl Med"},{"key":"2755_CR30","doi-asserted-by":"publisher","first-page":"e00766","DOI":"10.1128\/AAC.00766-18","volume":"62","author":"J-J Yoon","year":"2018","unstructured":"Yoon J-J, Toots M, Lee S, Lee M-E, Ludeke B, Luczo JM, et al. Orally efficacious Broad-Spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses. Antimicrob Agents Chemother. 2018;62:e00766\u201318. https:\/\/doi.org\/10.1128\/AAC.00766-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"2755_CR31","doi-asserted-by":"publisher","first-page":"eabl7430","DOI":"10.1126\/scitranslmed.abl7430","volume":"14","author":"WA Fischer","year":"2022","unstructured":"Fischer WA, Eron JJ, Holman W, Cohen MS, Fang L, Szewczyk LJ, et al. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci Transl Med. 2022;14:eabl7430. https:\/\/doi.org\/10.1126\/scitranslmed.abl7430.","journal-title":"Sci Transl Med"},{"key":"2755_CR32","doi-asserted-by":"publisher","first-page":"eabb5883","DOI":"10.1126\/scitranslmed.abb5883","volume":"12","author":"TP Sheahan","year":"2020","unstructured":"Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020;12:eabb5883. https:\/\/doi.org\/10.1126\/scitranslmed.abb5883.","journal-title":"Sci Transl Med"},{"key":"2755_CR33","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.7326\/M22-0729","volume":"175","author":"MG Johnson","year":"2022","unstructured":"Johnson MG, Puenpatom A, Moncada PA, Burgess L, Duke ER, Ohmagari N, et al. Effect of molnupiravir on biomarkers, respiratory interventions, and medical services in COVID-19: A randomized, Placebo-Controlled trial. Ann Intern Med. 2022;175:1126\u201334. https:\/\/doi.org\/10.7326\/M22-0729.","journal-title":"Ann Intern Med"},{"key":"2755_CR34","doi-asserted-by":"publisher","first-page":"e00953","DOI":"10.1128\/aac.00953-23","volume":"68","author":"JM Strizki","year":"2024","unstructured":"Strizki JM, Gaspar JM, Howe JA, Hutchins B, Mohri H, Nair MS, et al. Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance. Antimicrob Agents Chemother. 2024;68:e00953\u201323. https:\/\/doi.org\/10.1128\/aac.00953-23.","journal-title":"Antimicrob Agents Chemother"},{"key":"2755_CR35","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41586-021-03312-w","volume":"591","author":"A Wahl","year":"2021","unstructured":"Wahl A, Gralinski LE, Johnson CE, Yao W, Kovarova M, Dinnon KH, et al. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature. 2021;591:451\u20137. https:\/\/doi.org\/10.1038\/s41586-021-03312-w.","journal-title":"Nature"},{"key":"2755_CR36","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","volume":"28","author":"F Kabinger","year":"2021","unstructured":"Kabinger F, Stiller C, Schmitzov\u00e1 J, Dienemann C, Kokic G, Hillen HS, et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol. 2021;28:740\u20136. https:\/\/doi.org\/10.1038\/s41594-021-00651-0.","journal-title":"Nat Struct Mol Biol"},{"key":"2755_CR37","doi-asserted-by":"publisher","first-page":"100770","DOI":"10.1016\/j.jbc.2021.100770","volume":"297","author":"CJ Gordon","year":"2021","unstructured":"Gordon CJ, Tchesnokov EP, Schinazi RF, G\u00f6tte M. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. J Biol Chem. 2021;297:100770. https:\/\/doi.org\/10.1016\/j.jbc.2021.100770.","journal-title":"J Biol Chem"},{"key":"2755_CR38","doi-asserted-by":"publisher","unstructured":"Agostini ML, Pruijssers AJ, Chappell JD, Gribble J, Lu X, Andres EL, et al. Small-molecule antiviral _-D-N4-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance. J Virol. 2019;93:e01348-19. https:\/\/doi.org\/10.1128\/JVI.01348-19","DOI":"10.1128\/JVI.01348-19"},{"key":"2755_CR39","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s13020-023-00843-4","volume":"18","author":"R Luo","year":"2023","unstructured":"Luo R, Lv C, Wang T, Deng X, Sima M, Guo J, et al. A potential Chinese medicine monomer against influenza A virus and influenza B virus: isoquercitrin. Chin Med. 2023;18:144. https:\/\/doi.org\/10.1186\/s13020-023-00843-4.","journal-title":"Chin Med"},{"key":"2755_CR40","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.virs.2023.05.011","volume":"38","author":"Z Wang","year":"2023","unstructured":"Wang Z, Yang S, Dai Q, Guo X, Li Y, Li W, et al. In vitro and in vivo efficacy of molnupiravir against Zika virus infections. Virol Sin. 2023;38:639\u201342. https:\/\/doi.org\/10.1016\/j.virs.2023.05.011.","journal-title":"Virol Sin"},{"key":"2755_CR41","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.trsl.2019.12.002","volume":"218","author":"M Toots","year":"2020","unstructured":"Toots M, Yoon J-J, Hart M, Natchus MG, Painter GR, Plemper RK. Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model. Translational Res. 2020;218:16\u201328. https:\/\/doi.org\/10.1016\/j.trsl.2019.12.002.","journal-title":"Translational Res"},{"key":"2755_CR42","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1056\/NEJMc2214302","volume":"388","author":"M Imai","year":"2023","unstructured":"Imai M, Ito M, Kiso M, Yamayoshi S, Uraki R, Fukushi S, et al. Efficacy of antiviral agents against Omicron subvariants BQ.1.1 and XBB. N Engl J Med. 2023;388:89\u201391. https:\/\/doi.org\/10.1056\/NEJMc2214302.","journal-title":"N Engl J Med"},{"key":"2755_CR43","doi-asserted-by":"publisher","first-page":"105252","DOI":"10.1016\/j.antiviral.2022.105252","volume":"198","author":"L Vangeel","year":"2022","unstructured":"Vangeel L, Chiu W, De Jonghe S, Maes P, Slechten B, Raymenants J, et al. Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Res. 2022;198:105252. https:\/\/doi.org\/10.1016\/j.antiviral.2022.105252.","journal-title":"Antiviral Res"},{"key":"2755_CR44","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1038\/s41467-022-32045-1","volume":"13","author":"CM Lieber","year":"2022","unstructured":"Lieber CM, Cox RM, Sourimant J, Wolf JD, Juergens K, Phung Q, et al. SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 Dwarf hamster model. Nat Commun. 2022;13:4416. https:\/\/doi.org\/10.1038\/s41467-022-32045-1.","journal-title":"Nat Commun"},{"key":"2755_CR45","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1038\/s41564-022-01170-4","volume":"7","author":"R Uraki","year":"2022","unstructured":"Uraki R, Kiso M, Imai M, Yamayoshi S, Ito M, Fujisaki S, et al. Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters. Nat Microbiol. 2022;7:1252\u20138. https:\/\/doi.org\/10.1038\/s41564-022-01170-4.","journal-title":"Nat Microbiol"},{"key":"2755_CR46","doi-asserted-by":"publisher","first-page":"21259","DOI":"10.1038\/s41598-021-00809-2","volume":"11","author":"T Kinoshita","year":"2021","unstructured":"Kinoshita T, Watanabe K, Sakurai Y, Nishi K, Yoshikawa R, Yasuda J. Co-infection of SARS-CoV-2 and influenza virus causes more severe and prolonged pneumonia in hamsters. Sci Rep. 2021;11:21259. https:\/\/doi.org\/10.1038\/s41598-021-00809-2.","journal-title":"Sci Rep"},{"key":"2755_CR47","doi-asserted-by":"publisher","first-page":"e978","DOI":"10.1093\/cid\/ciaa1747","volume":"72","author":"AJ Zhang","year":"2021","unstructured":"Zhang AJ, Lee AC-Y, Chan JF-W, Liu F, Li C, Chen Y, et al. Coinfection by severe acute respiratory syndrome coronavirus 2 and influenza A(H1N1)pdm09 virus enhances the severity of pneumonia in golden Syrian hamsters. Clin Infect Dis. 2021;72:e978\u201392. https:\/\/doi.org\/10.1093\/cid\/ciaa1747.","journal-title":"Clin Infect Dis"},{"key":"2755_CR48","doi-asserted-by":"publisher","first-page":"5819","DOI":"10.1038\/s41467-021-26113-1","volume":"12","author":"H Achdout","year":"2021","unstructured":"Achdout H, Vitner EB, Politi B, Melamed S, Yahalom-Ronen Y, Tamir H, et al. Increased lethality in influenza and SARS-CoV-2 coinfection is prevented by influenza immunity but not SARS-CoV-2 immunity. Nat Commun. 2021;12:5819. https:\/\/doi.org\/10.1038\/s41467-021-26113-1.","journal-title":"Nat Commun"},{"key":"2755_CR49","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41577-022-00784-3","volume":"23","author":"Y Chen","year":"2023","unstructured":"Chen Y, Zhao X, Zhou H, Zhu H, Jiang S, Wang P. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Nat Rev Immunol. 2023;23:189\u201399. https:\/\/doi.org\/10.1038\/s41577-022-00784-3.","journal-title":"Nat Rev Immunol"},{"key":"2755_CR50","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/irv.12917","volume":"16","author":"J McCauley","year":"2022","unstructured":"McCauley J, Barr IG, Nolan T, Tsai T, Rockman S, Taylor B. The importance of influenza vaccination during the COVID-19 pandemic. Influenza Resp Viruses. 2022;16:3\u20136. https:\/\/doi.org\/10.1111\/irv.12917.","journal-title":"Influenza Resp Viruses"},{"key":"2755_CR51","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41421-023-00631-2","volume":"10","author":"L Wang","year":"2024","unstructured":"Wang L, Jiao F, Jiang H, Yang Y, Huang Z, Wang Q, et al. Fusogenicity of SARS-CoV-2 BA.2.86 subvariant and its sensitivity to the prokaryotic Recombinant EK1 peptide. Cell Discov. 2024;10:6. https:\/\/doi.org\/10.1038\/s41421-023-00631-2.","journal-title":"Cell Discov"},{"key":"2755_CR52","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.puhe.2023.12.009","volume":"227","author":"C Leung","year":"2024","unstructured":"Leung C, Konya L, Su L. Postpandemic immunity debt of influenza in the USA and England: an interrupted time series study. Public Health. 2024;227:239\u201342. https:\/\/doi.org\/10.1016\/j.puhe.2023.12.009.","journal-title":"Public Health"},{"key":"2755_CR53","doi-asserted-by":"publisher","unstructured":"Park S-J, Yu K-M, Kim Y-I, Kim S-M, Kim E-H, Kim S-G et al. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets. mBio. 2020;11:e01114-20. https:\/\/doi.org\/10.1128\/mBio.01114-20","DOI":"10.1128\/mBio.01114-20"},{"key":"2755_CR54","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 \u2014 Final report. N Engl J Med. 2020;383:1813\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2007764.","journal-title":"N Engl J Med"},{"key":"2755_CR55","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","volume":"22","author":"G Li","year":"2023","unstructured":"Li G, Hilgenfeld R, Whitley R, De Clercq E. Therapeutic strategies for COVID-19: progress and lessons learned. Nat Rev Drug Discov. 2023;22:449\u201375. https:\/\/doi.org\/10.1038\/s41573-023-00672-y.","journal-title":"Nat Rev Drug Discov"},{"key":"2755_CR56","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.trsl.2019.12.002","volume":"218","author":"M Toots","year":"2020","unstructured":"Toots M, Yoon J-J, Hart M, Natchus MG, Painter GR, Plemper RK. Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model. Transl Res. 2020;218:16\u201328. https:\/\/doi.org\/10.1016\/j.trsl.2019.12.002.","journal-title":"Transl Res"},{"key":"2755_CR57","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.coviro.2021.06.003","volume":"50","author":"GR Painter","year":"2021","unstructured":"Painter GR, Natchus MG, Cohen O, Holman W, Painter WP. Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19. Curr Opin Virol. 2021;50:17\u201322. https:\/\/doi.org\/10.1016\/j.coviro.2021.06.003.","journal-title":"Curr Opin Virol"},{"key":"2755_CR58","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1128\/AAC.47.1.244-254.2003","volume":"47","author":"LJ Stuyver","year":"2003","unstructured":"Stuyver LJ, Whitaker T, McBrayer TR, Hernandez-Santiago BI, Lostia S, Tharnish PM, et al. Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. Antimicrob Agents Chemother. 2003;47:244\u201354. https:\/\/doi.org\/10.1128\/AAC.47.1.244-254.2003.","journal-title":"Antimicrob Agents Chemother"},{"key":"2755_CR59","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/cts.12840","volume":"13","author":"R Humeniuk","year":"2020","unstructured":"Humeniuk R, Mathias A, Cao H, Osinusi A, Shen G, Chng E, et al. Safety, tolerability, and pharmacokinetics of Remdesivir, an antiviral for treatment of COVID-19, in healthy subjects. Clin Translational Sci. 2020;13:896\u2013906. https:\/\/doi.org\/10.1111\/cts.12840.","journal-title":"Clin Translational Sci"},{"key":"2755_CR60","doi-asserted-by":"publisher","first-page":"e02428","DOI":"10.1128\/AAC.02428-20","volume":"65","author":"WP Painter","year":"2021","unstructured":"Painter WP, Holman W, Bush JA, Almazedi F, Malik H, Eraut NCJE, et al. Human safety, tolerability, and pharmacokinetics of Molnupiravir, a novel Broad-Spectrum oral antiviral agent with activity against SARS-CoV-2. Antimicrob Agents Chemother. 2021;65:e02428\u201320. https:\/\/doi.org\/10.1128\/AAC.02428-20.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02755-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-025-02755-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02755-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T15:20:16Z","timestamp":1745853616000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-025-02755-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2755"],"URL":"https:\/\/doi.org\/10.1186\/s12985-025-02755-1","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"assertion":[{"value":"19 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study and included experimental procedures were conducted in accordance with the Declaration of Helsinki, and approved by the institutional animal care and use committee of Changchun Veterinary Research Institute (IACUC-AMMS-11-2023-001). All animal housing and experiments were performed in strict accordance with ethical guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"126"}}